DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
The generic ingredient in GIVLAARI is givosiran sodium. Additional details are available on the givosiran sodium profile page.
DrugPatentWatch® Estimated Generic Entry Opportunity Date for 212194
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Profile for product number 001
|Active Rx/OTC/Discontinued:||RX||Dosage:||SOLUTION;SUBCUTANEOUS||Strength||EQ 189MG BASE/ML (EQ 189MG BASE/ML)|
|Approval Date:||Nov 20, 2019||TE:||RLD:||Yes|
|Regulatory Exclusivity Expiration:||Nov 20, 2026|
|Regulatory Exclusivity Use:||INDICATED FOR THE TREATMENT OF ADULTS WITH ACUTE HEPATIC PORPHYRIA (AHP)|
|Regulatory Exclusivity Expiration:||Nov 20, 2024|
|Regulatory Exclusivity Use:||NEW CHEMICAL ENTITY|
|Patent:||⤷ Free Forever Trial||Patent Expiration:||Oct 3, 2034||Product Flag?||Y||Substance Flag?||Y||Delist Request?|
|Patented Use:||TREATMENT OF ACUTE HEPATIC PORPHYRIA|
Complete Access Available with Subscription